PriceTargets.com logo

Arcutis Biotherapeutics - ARQT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $26.56
  • Forecasted Upside: 205.94%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$8.68 As of 04/26/2024 02:58 PM ET
▲ +0.09 (1.05%)

This chart shows the closing price for ARQT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcutis Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARQT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARQT

Analyst Price Target is $26.56
▲ +205.94% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $26.56, with a high forecast of $50.00 and a low forecast of $8.00. The average price target represents a 205.94% upside from the last price of $8.68.

This chart shows the closing price for ARQT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in Arcutis Biotherapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$16.00Low
2/28/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$6.00 ➝ $11.00Low
2/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $16.00Low
2/23/2024MizuhoReiterated RatingBuy ➝ Buy$8.00 ➝ $16.00Low
1/2/2024MizuhoUpgradeNeutral ➝ Buy$4.00 ➝ $8.00Low
11/13/2023Morgan StanleyLower TargetOverweight ➝ Overweight$45.00 ➝ $10.00Low
11/8/2023JonestradingReiterated RatingBuy ➝ HoldLow
11/6/2023HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $8.00Low
11/6/2023Needham & Company LLCLower TargetBuy ➝ Buy$22.00 ➝ $8.00Low
10/26/2023MizuhoDowngradeBuy ➝ NeutralLow
10/13/2023The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$32.00 ➝ $6.00Low
9/25/2023MizuhoReiterated RatingBuy ➝ Buy$57.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00Low
8/9/2023TD CowenLower TargetOutperform ➝ Outperform$65.00 ➝ $50.00N/A
7/17/2023GuggenheimLower Target$45.00 ➝ $38.00Low
6/12/2023500.comReiterated RatingReiteratesLow
5/26/2023Truist FinancialLower Target$45.00 ➝ $40.00Low
5/10/2023MizuhoLower Target$61.00 ➝ $57.00Low
4/19/2023Needham & Company LLCReiterated RatingBuy$24.00Low
4/12/2023Morgan StanleyLower TargetOverweight$50.00 ➝ $47.00Low
4/11/2023MizuhoReiterated RatingBuy$61.00Low
3/29/2023Truist FinancialLower TargetBuy$50.00 ➝ $45.00Low
3/16/2023Needham & Company LLCLower TargetBuy$46.00 ➝ $24.00Low
3/1/2023Cantor FitzgeraldReiterated RatingOverweightLow
3/1/2023Needham & Company LLCReiterated RatingBuy$46.00Low
3/1/2023Morgan StanleyLower TargetOverweight$51.00 ➝ $50.00Low
12/13/2022Morgan StanleyBoost TargetOverweight$49.00 ➝ $51.00Low
10/4/2022Morgan StanleyBoost TargetOverweight$46.00 ➝ $49.00Low
9/27/2022Morgan StanleyBoost TargetOverweight$45.00 ➝ $46.00Low
9/22/2022JonestradingReiterated RatingBuy$54.00Low
9/7/2022Needham & Company LLCInitiated CoverageBuy$46.00Low
8/2/2022The Goldman Sachs GroupBoost TargetBuy$45.00 ➝ $50.00Low
8/2/2022Morgan StanleyBoost TargetOverweight$39.00 ➝ $45.00Low
6/7/2022Morgan StanleyBoost TargetOverweight$36.00 ➝ $39.00Medium
4/7/2022MizuhoLower TargetBuy$58.00 ➝ $57.00Medium
3/25/2022MizuhoReiterated RatingBuy$58.00Low
3/17/2022The Goldman Sachs GroupInitiated CoverageBuy$45.00High
3/2/2022Morgan StanleyBoost TargetOverweight$35.00 ➝ $37.00Medium
2/23/2022Cantor FitzgeraldReiterated RatingOverweightHigh
12/23/2021MizuhoReiterated RatingBuy$58.00High
11/19/2021Morgan StanleyLower TargetOverweight$50.00 ➝ $35.00High
10/1/2021MizuhoReiterated RatingBuy$58.00Medium
7/16/2021Morgan StanleyLower TargetOverweight$52.00 ➝ $50.00High
6/29/2021MizuhoInitiated CoverageBuy$58.00High
5/27/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$52.00High
2/2/2021Truist FinancialBoost Target$38.00 ➝ $48.00Low
2/1/2021CowenBoost TargetOutperform$55.00 ➝ $80.00Low
1/28/2021JonestradingInitiated CoverageBuyHigh
11/9/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$34.00 ➝ $36.00High
10/8/2020Truist FinancialInitiated CoverageBuy$38.00Medium
3/20/2020Cantor FitzgeraldReiterated RatingBuy$50.00High
2/25/2020The Goldman Sachs GroupInitiated CoverageNeutral$30.00High
2/25/2020GuggenheimInitiated CoverageBuy$36.00High
2/25/2020CowenInitiated CoverageOutperform$55.00High
2/25/2020Cantor FitzgeraldInitiated CoverageOverweight$50.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 9 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 10 very positive mentions
  • 30 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/27/2024
  • 6 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 6 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Arcutis Biotherapeutics logo
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More

Today's Range

Now: $8.68
Low: $8.36
High: $8.85

50 Day Range

MA: $10.18
Low: $8.59
High: $12.53

52 Week Range

Now: $8.68
Low: $1.76
High: $15.21

Volume

782,594 shs

Average Volume

4,579,982 shs

Market Capitalization

$840.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcutis Biotherapeutics?

The following equities research analysts have issued stock ratings on Arcutis Biotherapeutics in the last twelve months: 500.com Limited, Cantor Fitzgerald, Guggenheim, HC Wainwright, Jonestrading, Mizuho, Morgan Stanley, Needham & Company LLC, TD Cowen, The Goldman Sachs Group, Inc., and Truist Financial Co..
View the latest analyst ratings for ARQT.

What is the current price target for Arcutis Biotherapeutics?

9 Wall Street analysts have set twelve-month price targets for Arcutis Biotherapeutics in the last year. Their average twelve-month price target is $26.56, suggesting a possible upside of 205.9%. Cantor Fitzgerald has the highest price target set, predicting ARQT will reach $50.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Arcutis Biotherapeutics in the next year.
View the latest price targets for ARQT.

What is the current consensus analyst rating for Arcutis Biotherapeutics?

Arcutis Biotherapeutics currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARQT.

What other companies compete with Arcutis Biotherapeutics?

Other companies that are similar to Arcutis Biotherapeutics include 89bio, Tyra Biosciences, Tango Therapeutics, OPKO Health and ARS Pharmaceuticals. Learn More about companies similar to Arcutis Biotherapeutics.

How do I contact Arcutis Biotherapeutics' investor relations team?

Arcutis Biotherapeutics' physical mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company's listed phone number is 805-418-5006 and its investor relations email address is [email protected]. The official website for Arcutis Biotherapeutics is www.arcutis.com. Learn More about contacing Arcutis Biotherapeutics investor relations.